C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) – Pipeline Review, H2 2016’, provides in depth analysis on C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3)

The report reviews C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Mitsubishi Tanabe Pharma Corporation

Pharmaxis Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) Overview 6

Therapeutics Development 7

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Stage of Development 7

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Therapy Area 8

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Indication 9

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Companies 12

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Companies Involved in Therapeutics Development 21

Mitsubishi Tanabe Pharma Corporation 21

Pharmaxis Limited 22

Toray Industries, Inc. 23

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Drug Profiles 24

ASM-8 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CM-101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MT-0814 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

PXS-2200 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecule to Antagonize CCR3 for Undisclosed Indication - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Dormant Projects 30

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Discontinued Products 31

C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Featured News & Press Releases 32

Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 32

Sep 29, 2011: Pharmaxis Completes Enrollment In Phase II Asthma Study 32

Dec 07, 2010: Pharmaxis Initiates Phase II Trial Of ASM8 In Asthma Patients 33

Mar 11, 2010: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 33

Jan 12, 2009: TOPIGEN Pharmaceuticals Reports Phase 2 Results Of TPI ASM8 In Asthma Patients 34

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 21

Pipeline by Pharmaxis Limited, H2 2016 22

Pipeline by Toray Industries, Inc., H2 2016 23

Dormant Projects, H2 2016 30

Discontinued Products, H2 2016 31

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports